Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus; [Radiochemotherapie mit und ohne regionale Tiefenhyperthermie bei Plattenepithelkarzinomen des Anus]

被引：0

作者：

Ott O.J. ^{[1
]}

Schmidt M. ^{[1
]}

Semrau S. ^{[1
]}

Strnad V. ^{[1
]}

Matzel K.E. ^{[2
]}

Schneider I. ^{[2
]}

Raptis D. ^{[2
]}

Uter W. ^{[3
]}

Grützmann R. ^{[2
]}

Fietkau R. ^{[1
]}

机构：

[1] Department of Radiation Oncology, Universitätsklinikum Erlangen, Universitätsstr. 27, Erlangen

[2] Department of Surgery, Universitätsklinikum Erlangen, Erlangen

[3] Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen

来源：

Strahlentherapie und Onkologie | 2019年 / 195卷 / 7期

关键词：

Anal cancer; Chemoradiation; Deep regional hyperthermia; Multimodality treatment; Radiotherapy;

D O I：

10.1007/s00066-018-1396-x

中图分类号：

学科分类号：

摘要：

Purpose: To compare results after chemoradiotherapy with and without deep regional hyperthermia in patients with anal cancer. Methods: Between 2000 and 2015, a total of 112 consecutive patients with UICC stage I–IV anal cancer received chemoradiotherapy with 5‑fluororuracil and mitomycin C (CRT). In case of insufficient tumor response 4–6 weeks after chemoradiotherapy, patients received an interstitial pulsed-dose-rate brachytherapy boost. Additionally, 50/112 patients received hyperthermia treatments (HCRT). Results: Median follow-up was 41 (2–165) months. After 5 years follow-up, overall (95.8 vs. 74.5%, P = 0.045), disease-free (89.1 vs. 70.4%, P = 0.027), local recurrence-free (97.7 vs. 78.7%, P = 0.006), and colostomy-free survival rates (87.7 vs. 69.0%, P = 0.016) were better for the HCRT group. Disease-specific, regional failure-free, and distant metastasis-free survival rates showed no significant differences. The adjusted hazard ratios for death were 0.25 (95% CI, 0.07 to 0.92; P = 0.036) and for local recurrence 0.14 (95% CI, 0.02 to 1.09; P = 0.06), respectively. Grades 3–4 early toxicities were comparable with the exception of hematotoxicity, which was higher in the HCRT group (66 vs. 43%, P = 0.032). Incidences of late side effects were similar with the exception of a higher telangiectasia rate in the HCRT group (38.0 vs. 16.1%, P = 0.009). Conclusion: Additional regional hyperthermia improved overall survival, local control, and colostomy rates. Its potential beneficial role has to be confirmed in a prospective randomized setting. Therefore, the HyCAN trial has already been established by our group and is currently recruiting patients (Clinicaltrials.gov identifier: NCT02369939). © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

引用

页码：607 / 614

页数：7

共 19 条

[1]

Bartelink H., Roelofsen F., Eschwege F., Et al., Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups, J Clin Oncol, 15, pp. 2040-2049, (1997)

[2]

Flam M., John M., Pajak T.F., Et al., Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study, J Clin Oncol, 14, pp. 2527-2539, (1996)

[3]

Gunderson L.L., Winter K.A., Ajani J.A., Et al., Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin, J Clin Oncol, 30, pp. 4344-4351, (2012)

[4]

Henkenberens C., Meinecke D., Michael S., Et al., Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: Back to the roots?, Strahlenther Onkol, 191, pp. 845-854, (2015)

[5]

Issels R.D., Hyperthermia adds to chemotherapy, Eur J Cancer, 44, pp. 2546-2554, (2008)

[6]

Issels R.D., Lindner L.H., Verweij J., Et al., Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study, Lancet Oncol, 11, pp. 561-570, (2010)

[7]

James R.D., Glynne-Jones R., Meadows H.M., Et al., Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 x 2 factorial trial, Lancet Oncol, 14, pp. 516-524, (2013)

[8]

Jones E.L., Oleson J.R., Prosnitz L.R., Et al., Randomized trial of hyperthermia and radiation for superficial tumors, J Clin Oncol, 23, pp. 3079-3085, (2005)

[9]

Kapacee Z.A., Susnerwala S., Wise M., Et al., Chemoradiotherapy for squamous cell anal carcinoma: A review of prognostic factors, Colorectal Dis, 18, 11, pp. 1080-1086, (2016)

[10]

Kent C., Bessell E.M., Scholefield J.H., Et al., Chemoradiotherapy with Brachytherapy or electron therapy boost for locally advanced squamous cell carcinoma of the anus-reducing the colostomy rate, J Gastrointest Cancer, 48, 1, pp. 1-7, (2016)

← 1 2 →